Chicago Ventures

Layup is a savings account that provides prizes based on the outcomes of sporting events.

Nemaura Medical Inc. is a medical technology company focused on the development and commercialization of non-invasive wearable diagnostic devices. Founded in 2009 and based in New York, the company is known for its flagship product, sugarBEAT, a CE mark-approved continuous glucose monitor designed for individuals with Type I and Type II diabetes, as well as for pre-diabetic patients. This device provides real-time glucose measurements and daily trend data through a disposable adhesive skin patch linked to a rechargeable transmitter. By offering actionable insights, sugarBEAT aims to help users effectively manage, reverse, and prevent the onset of diabetes. Nemaura Medical also holds a license agreement with Healthimation, allowing it to offer an intensive medical diabetes and weight management program, along with related applications and trademarks.

Nemaura Medical Inc. is a medical technology company focused on the development and commercialization of non-invasive wearable diagnostic devices. Founded in 2009 and based in New York, the company is known for its flagship product, sugarBEAT, a CE mark-approved continuous glucose monitor designed for individuals with Type I and Type II diabetes, as well as for pre-diabetic patients. This device provides real-time glucose measurements and daily trend data through a disposable adhesive skin patch linked to a rechargeable transmitter. By offering actionable insights, sugarBEAT aims to help users effectively manage, reverse, and prevent the onset of diabetes. Nemaura Medical also holds a license agreement with Healthimation, allowing it to offer an intensive medical diabetes and weight management program, along with related applications and trademarks.

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing non-antibiotic anti-infective products for both the eye care and wound care markets. The company’s flagship product, Avenova, is an antimicrobial solution designed for cleansing the eyelids and lashes, effectively removing debris and microorganisms without causing irritation. Avenova is based on a proprietary formulation of hypochlorous acid, which mimics the natural antimicrobial properties of white blood cells. In addition to Avenova, NovaBay offers NeutroPhase, a skin and wound cleanser, and CelleRx, aimed at the aesthetic dermatology market. The company is also advancing auriclosene, a synthetic molecule with broad-spectrum efficacy against bacteria, viruses, and fungi, and has entered into a collaboration with Virbac to develop this compound for veterinary applications. NovaBay Pharmaceuticals was incorporated in 2000 and is headquartered in Emeryville, California.

GrowLife is a logistics company that serves as a cultivation facility service provider. It provides hydroponic equipment, lighting, nutrients, media, and other cultivation supplies to commercial and urban operations. With a complete selection of cultivation products combined with logistics and distribution services, GrowLife can help responsible cultivation operations efficiently control supply costs, manage build-out investments, track supply usage, and streamline workflows. GrowLife was founded in 1987 and headquartered in Seattle, Washington.

OncoVista Innovative Therapies, Inc., a biopharmaceutical company, focuses on commercializing diagnostic tests for metastatic tumors, as well as developing targeted anticancer therapies by utilizing tumor-associated biomarkers. The company has developed diagnostic kits for breast, colon, ovarian, and prostate cancers, and markets diagnostic kits in Europe for the detection of circulating tumor cells (CTCs) in patients with breast and colon cancer. Product and Product Candidate Pipeline The company's portfolio of compounds and technologies under development or planned development include: AdnaGen Oncology Diagnostics; A Liposomal TS Inhibitor; Cordycepin; L-Nucleoside Conjugates; and Novel Tubulin Isotype-Specific Anti-Mitotics. AdnaGen Diagnostic Products The company's subsidiary, AdnaGen A.G., offers diagnostic products for colon and breast cancer diagnosis in the European market. It has the ability to detect and recognize the expression of tumor-associated biomarkers in patients with metastatic cancer. In September 2008, AdnaGen entered into a distribution and license agreement with Biomarkers LLC (Biomarkers) granting Biomarkers the right to distribute the AdnaGen diagnostic kits in North America. AdnaGen also entered into a distribution and license agreement with Biomarkers granting Biomarkers the right to distribute the AdnaGen diagnostic kits in South America and the Middle East. In January 2007, AdnaGen entered into a distribution agreement with Innogenetics N.V. (Innogenetics) granting Innogenetics the right to commercialize the AdnaGen diagnostic kits in the European market. In September 2007, AdnaGen entered into a license agreement with Innogenetics granting Innogenetics the right to use AdnaGen technology in adapting Innogenetics' proprietary strip detection technology after successful feasibility studies. Liposomal Thymidylate Synthase (TS) Inhibitor (OVI-237) (solid tumors) OVI-237 is the company's advanced clinical stage drug. OVI-237 is a liposome encapsulated formulation of a potent thymidylate synthase inhibitor (TSI) with activity at picomolar concentrations. It was obtained as a result of a worldwide licensing agreement with OSI Pharmaceuticals (Melville, New York). With OVI-237, it has finalized the protocol and selected clinical sites to conduct a Phase II Study of OVI-237 monotherapy and combination therapy with cisplatin for the treatment of metastatic breast cancer. Cordycepin (OVI-123) (TdT-Positive Refractory Leukemias) The company is developing Cordycepin as a treatment option for certain leukemia patients that are either refractory to chemotherapeutics or have experienced a relapse. Cordycepin depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for its therapeutic activity. Cordycepin has been studied in a National Cancer Institute-sponsored Phase I clinical trial for treating TdT-positive ALL leukemia patients. It initiated a Phase I/II trial based on the ‘original' ADA-sensitive compound. L-Nucleoside Conjugate (OVI-117): The company has accumulated in vitro and in vivo data indicating that the L-nucleoside conjugates are effective against various types of cancer. One of its L-nucleoside conjugate candidates, OVI-117, is a conjugate of an L-nucleoside (L-uridine) and the highly toxic compound 5'-fluorodeoxyuridine monophosphate (FdUMP), a thymidylate synthase (TS) inhibitor. Tubulin Isotype-Specific Anti-mitotics The company's other platform technology relates to a proprietary database of tubulin isotypes as potential candidates for targeting by certain chemotherapeutics. It is evaluating various candidates as part of its research and development in this area. Collaborative Relationships and Partnerships The company has relationships with the University of Texas Health Science Center at San Antonio (UTHSCSA), the Cancer Therapy and Research Center (CTRC), the Dana-Farber Cancer Institute, MD Anderson Cancer Center and the San Antonio Cancer Institute (SACI), a cancer research institute. Competition The company's competitors include Amgen, Inc.; Genentech, Inc.; Biogen Idec Inc.; Eli Lilly & Co.; OSI Pharmaceuticals, Inc.; Avalon; Kosan; Allos; EntreMed; Threshold Pharmaceuticals; Vion Pharmaceuticals; Cougar Biotechnology; Sunesis; Abbott Diagnostic Laboratories; Aureon Laboratories; Celera Diagnostics, LLC; Correlogic Systems; Genomic Health; Monogram Biosciences; Myriad Genetics; Roche Diagnostics; and Veridex LLC. History OncoVista Innovative Therapies, Inc. was incorporated in 2004.

IKANO Communications, founded over a decade ago, is a prominent Internet service provider in the Intermountain West, specializing in private-label, wholesale, and retail Internet services. The company has established a strong reputation for delivering competitive pricing and high-quality services. IKANO offers a wide range of solutions, including wholesale DSL, hosted voice services, internet call center support, web and mail hosting, and billing services. By leveraging its ISP platform and partnerships with telecommunications companies, IKANO effectively supports organizations in enhancing customer acquisition, communication, and retention through their e-business initiatives. Notably, IKANO served as the official Data Networking Services Provider for the 2002 Olympic and Paralympic Winter Games, showcasing its capabilities in delivering robust data networking services.